CD19 and neoplasm: In summary, we developed a new CART19 product from bench to bedside and demonstrated that targeting a novel membrane-proximal epitope of CD19 with fast on- and off-rate CAR leads to a potent anti-tumor effect in patients with manageable toxicity.